Rosen Law Firm has initiated a class action lawsuit against Inovio Pharmaceuticals Inc. on behalf of investors who purchased the company's securities between October 10, 2023 and December 26, 2025. The litigation alleges that Inovio made materially false and misleading statements to the market regarding its business operations and regulatory prospects during the class period.
According to the complaint, the pharmaceutical company allegedly concealed manufacturing deficiencies affecting its CELLECTRA device and made overstatements regarding the regulatory pathway and commercial viability of its INO-3107 drug candidate. Additionally, the lawsuit contends that Inovio failed to adequately disclose that its previously communicated FDA submission timeline was unlikely to be achieved, thereby misleading investors about the company's near-term operational milestones.
Investors who acquired Inovio securities during the specified period may qualify as class members in the action. The deadline to serve as lead plaintiff in the case is April 7, 2026. Eligible investors are encouraged to consult with legal counsel regarding their potential claims and rights under securities law.